EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Carrier Proteins
/ genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Treatment Outcome
Triple Negative Breast Neoplasms
/ drug therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 05 2020
14 05 2020
Historique:
received:
03
10
2019
accepted:
27
04
2020
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
15
12
2020
Statut:
epublish
Résumé
EHD2 is a mechanotransducing ATPase localized in caveolae invaginations at the plasma membrane. EHD2 has recently been associated with several human cancers, however the significance of EHD2 transcript levels in cancer prognosis remains debated. Breast cancer is the most commonly occurring cancer in women and prognosis is variable depending on the subtypes. Triple negative breast cancer (TNBC) often has a poor therapeutic response. The aim of this study was to assess the prognostic significance of EHD2 transcripts and protein expression levels in breast carcinomas. We found that low EHD2 levels were associated with enhanced proliferation, migration and invasion of TNBC cells. EHD2 expression was significantly reduced in TNBC tissues and the loss of EHD2 led to higher expression of the pro-tumoral cytokine IL-8. In apparent contradiction with in vitro data, multivariate analysis of two independent cohorts of breast cancer patients revealed that low EHD2 was in fact associated with good prognosis in the highly proliferative TNBC subtype. Accordingly, TNBC low EHD2 expressers were found to benefit the most from chemotherapy when compared to all subtypes of breast cancers. Our study validates EHD2 expression level as an independent prognostic factor of metastasis-free survival and as a new predictive marker of chemotherapy efficacy in TNBC patients.
Identifiants
pubmed: 32409676
doi: 10.1038/s41598-020-65054-5
pii: 10.1038/s41598-020-65054-5
pmc: PMC7224205
doi:
Substances chimiques
Biomarkers, Tumor
0
Carrier Proteins
0
EHD2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7998Références
Stoeber, M. et al. Oligomers of the ATPase EHD2 confine caveolae to the plasma membrane through association with actin. EMBO J. 31, 2350–2364, https://doi.org/10.1038/emboj.2012.98 (2012).
doi: 10.1038/emboj.2012.98
pubmed: 22505029
pmcid: 3364743
Moren, B. et al. EHD2 regulates caveolar dynamics via ATP-driven targeting and oligomerization. Mol. Biol. Cell 23, 1316–1329, https://doi.org/10.1091/mbc.E11-09-0787 (2012).
doi: 10.1091/mbc.E11-09-0787
pubmed: 22323287
pmcid: 3315815
Torrino, S. et al. EHD2 is a mechanotransducer connecting caveolae dynamics with gene transcription. J Cell Biol, https://doi.org/10.1083/jcb.201801122 (2018).
Li, M. et al. Effects of EHD2 interference on migration of esophageal squamous cell carcinoma. Med. Oncol. 30, 396, https://doi.org/10.1007/s12032-012-0396-4 (2013).
doi: 10.1007/s12032-012-0396-4
pubmed: 23354948
pmcid: 3586404
Bignotti, E. et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 103, 405–416, https://doi.org/10.1016/j.ygyno.2006.03.056 (2006).
doi: 10.1016/j.ygyno.2006.03.056
pubmed: 16725184
Welinder, C. et al. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS One 12, e0176167, https://doi.org/10.1371/journal.pone.0176167 (2017).
doi: 10.1371/journal.pone.0176167
pubmed: 28445515
pmcid: 5405986
Liu, J. et al. Decreased Expression of EHD2 Promotes Tumor Metastasis and Indicates Poor Prognosis in Hepatocellular Carcinoma. Dig. Dis. Sci. 61, 2554–2567, https://doi.org/10.1007/s10620-016-4202-6 (2016).
doi: 10.1007/s10620-016-4202-6
pubmed: 27221498
Yang, X., Ren, H., Yao, L., Chen, X. & He, A. Role of EHD2 in migration and invasion of human breast cancer cells. Tumour Biol. 36, 3717–3726, https://doi.org/10.1007/s13277-014-3011-9 (2015).
doi: 10.1007/s13277-014-3011-9
pubmed: 25557791
Shi, Y. et al. Decreased expression and prognostic role of EHD2 in human breast carcinoma: correlation with E-cadherin. J. Mol. Histol. 46, 221–231, https://doi.org/10.1007/s10735-015-9614-7 (2015).
doi: 10.1007/s10735-015-9614-7
pubmed: 25758127
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424, https://doi.org/10.3322/caac.21492 (2018).
doi: 10.3322/caac.21492
pubmed: 30207593
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752, https://doi.org/10.1038/35021093 (2000).
doi: 10.1038/35021093
pubmed: 10963602
Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938–1948, https://doi.org/10.1056/NEJMra1001389 (2010).
doi: 10.1056/NEJMra1001389
pubmed: 21067385
Harbeck, N. & Gnant, M. Breast cancer. Lancet 389, 1134–1150, https://doi.org/10.1016/S0140-6736(16)31891-8 (2017).
doi: 10.1016/S0140-6736(16)31891-8
pubmed: 27865536
pmcid: 27865536
Morris, S. R. & Carey, L. A. Molecular profiling in breast cancer. Rev. Endocr. Metab. Disord. 8, 185–198, https://doi.org/10.1007/s11154-007-9035-3 (2007).
doi: 10.1007/s11154-007-9035-3
pubmed: 17464566
Aydiner, A. et al. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment. Medicine 94, e2341, https://doi.org/10.1097/MD.0000000000002341 (2015).
doi: 10.1097/MD.0000000000002341
pubmed: 26717372
pmcid: 5291613
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674–690, https://doi.org/10.1038/nrclinonc.2016.66 (2016).
doi: 10.1038/nrclinonc.2016.66
pubmed: 27184417
pmcid: 5461122
Campbell, L. M., Maxwell, P. J. & Waugh, D. J. Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals 6, 929–959, https://doi.org/10.3390/ph6080929 (2013).
doi: 10.3390/ph6080929
pubmed: 24276377
pmcid: 3817732
Singh, J. K., Simoes, B. M., Howell, S. J., Farnie, G. & Clarke, R. B. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 15, 210, https://doi.org/10.1186/bcr3436 (2013).
doi: 10.1186/bcr3436
pubmed: 24041156
pmcid: 3978717
Cai, B. et al. Differential roles of C-terminal Eps15 homology domain proteins as vesiculators and tubulators of recycling endosomes. J. Biol. Chem. 288, 30172–30180, https://doi.org/10.1074/jbc.M113.488627 (2013).
doi: 10.1074/jbc.M113.488627
pubmed: 24019528
pmcid: 3798485
Lamaze, C., Tardif, N., Dewulf, M., Vassilopoulos, S. & Blouin, C. M. The caveolae dress code: structure and signaling. Curr. Opin. Cell Biol. 47, 117–125, https://doi.org/10.1016/j.ceb.2017.02.014 (2017).
doi: 10.1016/j.ceb.2017.02.014
pubmed: 28641181
Yeow, I. et al. EHD Proteins Cooperate to Generate Caveolar Clusters and to Maintain Caveolae during Repeated Mechanical Stress. Curr. Biol. 27, 2951–2962 e2955, https://doi.org/10.1016/j.cub.2017.07.047 (2017).
doi: 10.1016/j.cub.2017.07.047
pubmed: 28943089
pmcid: 5640515
Inoue, K. et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 60, 2290–2299 (2000).
pubmed: 10786697
Kitadai, Y. et al. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br. J. Cancer 81, 647–653, https://doi.org/10.1038/sj.bjc.6690742 (1999).
doi: 10.1038/sj.bjc.6690742
pubmed: 10574250
pmcid: 2362886
Singh, R. K. & Lokeshwar, B. L. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol. Cancer 8, 57, https://doi.org/10.1186/1476-4598-8-57 (2009).
doi: 10.1186/1476-4598-8-57
pubmed: 19646263
pmcid: 2729725
Ha, H., Debnath, B. & Neamati, N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics 7, 1543–1588, https://doi.org/10.7150/thno.15625 (2017).
doi: 10.7150/thno.15625
pubmed: 28529637
pmcid: 28529637
Kim, Y. et al. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma. PLoS One 12, e0174737, https://doi.org/10.1371/journal.pone.0174737 (2017).
doi: 10.1371/journal.pone.0174737
pubmed: 28358874
pmcid: 5373597
Lamaze, C. & Torrino, S. Caveolae and cancer: A new mechanical perspective. Biomed. J. 38, 367–379, https://doi.org/10.4103/2319-4170.164229 (2015).
doi: 10.4103/2319-4170.164229
pubmed: 26345539
Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750–2767, https://doi.org/10.1172/JCI45014 (2011).
doi: 10.1172/JCI45014
pubmed: 21633166
pmcid: 3127435
Amadori, D. et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res. Treat. 43, 7–14 (1997).
doi: 10.1023/A:1005780107879
Prat, A. et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 31, 203–209, https://doi.org/10.1200/JCO.2012.43.4134 (2013).
doi: 10.1200/JCO.2012.43.4134
pubmed: 23233704
Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118–145, https://doi.org/10.1200/JCO.2006.09.2775 (2007).
doi: 10.1200/JCO.2006.09.2775
pubmed: 17159189
Vincent-Salomon, A. et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br. J. Cancer 96, 654–659, https://doi.org/10.1038/sj.bjc.6603584 (2007).
doi: 10.1038/sj.bjc.6603584
pubmed: 17262082
pmcid: 2360046
Bieche, I. et al. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20, 8109–8115, https://doi.org/10.1038/sj.onc.1204917 (2001).
doi: 10.1038/sj.onc.1204917
pubmed: 11781824
Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J. Cancer 16, 1513–1515, https://doi.org/10.1016/0014-2964(80)90064-x (1980).
Langton, B. C. et al. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res. 51, 2593–2598 (1991).
pubmed: 1673637
Bieche, I. et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin. Chem. 45, 1148–1156 (1999).
doi: 10.1093/clinchem/45.8.1148
Meseure, D. et al. Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value. Mol. Cancer Res. 14, 623–633, https://doi.org/10.1158/1541-7786.MCR-15-0418 (2016).
doi: 10.1158/1541-7786.MCR-15-0418
pubmed: 27102007
Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36, https://doi.org/10.1148/radiology.143.1.7063747 (1982).
doi: 10.1148/radiology.143.1.7063747
pubmed: 7063747
pmcid: 7063747